Proline-mediated proteasomal degradation of the prostate-specific tumor suppressor NKX3.1

Journal of Biological Chemistry

Volumn 287, Issue 43, 2012, Pages 36331-36340

  Rao, Varsha ^a,b   Guan, Bin ^a,c   Mutton, Laura N ^a   Bieberich, Charles J ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEGRADATION MECHANISM; ENHANCED GREEN FLUORESCENCE PROTEINS; HOMEODOMAIN TRANSCRIPTION FACTOR; IN-VIVO; MIMETICS; MUTATIONAL ANALYSIS; POST-TRANSLATIONAL MODIFICATIONS; PROLINE RESIDUES; PROSTATE CANCER CELLS; PROSTATE CANCER INITIATION; PROTEASOMAL DEGRADATION; PROTEASOMES; TUMOR SUPPRESSORS; UBIQUITINATION;

CELL CULTURE; DEGRADATION; DISEASES; PHOSPHORYLATION; TRANSCRIPTION FACTORS;

AMINO ACIDS;

PROTEIN NKX3.1; TRANSCRIPTION FACTOR ETS; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CODON; CONTROLLED STUDY; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; PEPTIDOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; UBIQUITINATION;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HOMEODOMAIN PROTEINS; HUMANS; MALE; MUTATION, MISSENSE; PEPTIDES; PHOSPHORYLATION; PROLINE; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN; UBIQUITINATION;

EID: 84867753118     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.352823     Document Type: Article

References (61)

1. Hoeller, D., Hecker, C. M., and Dikic, I. (2006) Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat. Rev. Cancer 6, 776-788 (Pubitemid 44450466)
2. Hershko, A. (2005) The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ. 12, 1191-1197
3. Hershko, A., Ciechanover, A., and Rose, I. A. (1979) Resolution of the ATP-dependent proteolytic system from reticulocytes: a component that interacts with ATP. Proc. Natl. Acad. Sci. U.S.A. 76, 3107-3110 (Pubitemid 9233240)
4. Wilkinson, K. D., Urban, M. K., and Haas, A. L. (1980) Ubiquitin is the ATP-dependent proteolysis factor I of rabbit reticulocytes. J. Biol. Chem. 255, 7529-7532 (Pubitemid 11239455)
5. Hershko, A., Ciechanover, A., Heller, H., Haas, A. L., and Rose, I. A. (1980) Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc. Natl. Acad. Sci. U.S.A. 77, 1783-1786
6. Jin, Y., Lee, H., Zeng, S. X., Dai, M. S., and Lu, H. (2003) MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J. 22, 6365-6377 (Pubitemid 37522593)
7. Sdek, P., Ying, H., Chang, D. L., Qiu, W., Zheng, H., Touitou, R., Allday, M. J., and Xiao, Z. X. (2005) MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol. Cell 20, 699-708 (Pubitemid 41740692)
8. Ying, H., and Xiao, Z. X. (2006) Targeting retinoblastoma protein for degradation by proteasomes. Cell Cycle 5, 506-508 (Pubitemid 43340528)
9. Hwang, J., Winkler, L., and Kalejta, R. F. (2011) Ubiquitin-independent proteasomal degradation during oncogenic viral infections. Biochim. Biophys. Acta 1816, 147-157
10. Sciavolino, P. J., Abrams, E. W., Yang, L., Austenberg, L. P., Shen, M. M., and Abate-Shen, C. (1997) Tissue-specific expression of murine Nkx3.1 in the male urogenital system. Dev. Dyn. 209, 127-138 (Pubitemid 27188345)
11. He, W. W., Sciavolino, P. J., Wing, J., Augustus, M., Hudson, P., Meissner, P. S., Curtis, R. T., Shell, B. K., Bostwick, D. G., Tindall, D. J., Gelmann, E. P., Abate-Shen, C., and Carter, K. C. (1997) A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 43, 69-77 (Pubitemid 27310524)
12. Bowen, C., Bubendorf, L., Voeller, H. J., Slack, R., Willi, N., Sauter, G., Gasser, T. C., Koivisto, P., Lack, E. E., Kononen, J., Kallioniemi, O. P., and Gelmann, E. P. (2000) Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 60, 6111-6115
13. Prescott, J. L., Blok, L., and Tindall, D. J. (1998) Isolation and androgen regulation of the human homeobox cDNA, NKX3.1. Prostate 35, 71-80 (Pubitemid 28158640)
14. De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., and Nelson, W. G. (2007) Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7, 256-269 (Pubitemid 46486616)
15. Abdulkadir, S. A., Magee, J. A., Peters, T. J., Kaleem, Z., Naughton, C. K., Humphrey, P. A., and Milbrandt, J. (2002) Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol. Cell. Biol. 22, 1495-1503 (Pubitemid 34150785)
16. Iwata, T., Schultz, D., Hicks, J., Hubbard, G. K., Mutton, L. N., Lotan, T. L., Bethel, C., Lotz, M. T., Yegnasubramanian, S., Nelson, W. G., Dang, C. V., Xu, M., Anele, U., Koh, C. M., Bieberich, C. J., and De Marzo, A. M. (2010) MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One 5, e9427
17. Kim, M. J., Bhatia-Gaur, R., Banach-Petrosky, W. A., Desai, N., Wang, Y., Hayward, S. W., Cunha, G. R., Cardiff, R. D., Shen, M. M., and Abate-Shen, C. (2002) Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res. 62, 2999-3004 (Pubitemid 34602384)
18. Magee, J. A., Abdulkadir, S. A., and Milbrandt, J. (2003) Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. Cancer Cell 3, 273-283 (Pubitemid 37443882)
19. Tulchin, N., Chambon, M., Juan, G., Dikman, S., Strauchen, J., Ornstein, L., Billack, B., Woods, N. T., and Monteiro, A. N. (2010) BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines. Am. J. Pathol. 176, 1203-1214
20. Bethel, C. R., Faith, D., Li, X., Guan, B., Hicks, J. L., Lan, F., Jenkins, R. B., Bieberich, C. J., and De Marzo, A. M. (2006) Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res. 66, 10683-10690 (Pubitemid 44876963)
21. Bethel, C. R., and Bieberich, C. J. (2007) Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model. Prostate 67, 1740-1750 (Pubitemid 350228726)
22. Patel, S., and Player, M. R. (2008) Small-molecule inhibitors of the p53- HDM2 interaction for the treatment of cancer. Expert Opin. Investig. Drugs 17, 1865-1882
23. Li, X., Guan, B., Maghami, S., and Bieberich, C. J. (2006) NKX3.1 is regulated by protein kinase CK2 in prostate tumor cells. Mol. Cell. Biol. 26, 3008-3017
24. Markowski, M. C., Bowen, C., and Gelmann, E. P. (2008) Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. Cancer Res. 68, 6896-6901
25. Guan, B., Pungaliya, P., Li, X., Uquillas, C., Mutton, L. N., Rubin, E. H., and Bieberich, C. J. (2008) Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1. J. Biol. Chem. 283, 4834-4840
26. Chen, H., and Bieberich, C. J. (2005) Structural and functional analysis of domains mediating interaction between NKX-3.1 and PDEF. J. Cell. Biochem. 94, 168-177 (Pubitemid 41420334)
27. Ferrara, P., Andermarcher, E., Bossis, G., Acquaviva, C., Brockly, F., Jariel- Encontre, I., and Piechaczyk, M. (2003) The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene 22, 1461-1474 (Pubitemid 36390595)
28. Wu, G., Wolf, J. B., Ibrahim, A. F., Vadasz, S., Gunasinghe, M., and Freeland, S. J. (2006) Simplified gene synthesis: a one-step approach to PCR-based gene construction. J. Biotechnol. 124, 496-503 (Pubitemid 43963520)
29. Zhang, H., Muders, M. H., Li, J., Rinaldo, F., Tindall, D. J., and Datta, K. (2008) Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res. 68, 8770-8778
30. Chen, H., Nandi, A. K., Li, X., and Bieberich, C. J. (2002) NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res. 62, 338-340 (Pubitemid 34106398)
31. Dohmen, R. J., Wu, P., and Varshavsky, A. (1994) Heat-inducible degron: a method for constructing temperature-sensitive mutants. Science 263, 1273-1276 (Pubitemid 24107546)
32. Jin, J., Shirogane, T., Xu, L., Nalepa, G., Qin, J., Elledge, S. J., and Harper, J. W. (2003) SCFβ-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev. 17, 3062-3074 (Pubitemid 38040770)
33. Ye, X., Nalepa, G., Welcker, M., Kessler, B. M., Spooner, E., Qin, J., Elledge, S. J., Clurman, B. E., and Harper, J. W. (2004) Recognition of phosphodegron motifs in human cyclin E by the SCF(Fbw7) ubiquitin ligase. J. Biol. Chem. 279, 50110-50119 (Pubitemid 39577823)
34. Herbst, A., Salghetti, S. E., Kim, S. Y., and Tansey, W. P. (2004) Multiple cell-type-specific elements regulate Myc protein stability. Oncogene 23, 3863-3871 (Pubitemid 38725699)
35. Acquaviva, C., Brockly, F., Ferrara, P., Bossis, G., Salvat, C., Jariel-Encontre, I., and Piechaczyk, M. (2001) Identification of a C-terminal tripeptide motif in the control of rapid proteasomal degradation of c-Fos protooncoprotein during the Go-to-S phase transition. Oncogene 20, 7563-7572 (Pubitemid 33086916)
36. Tovar, C., Higgins, B., Kolinsky, K., Xia, M., Packman, K., Heimbrook, D. C., and Vassilev, L. T. (2011) MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Mol. Cancer 10, 49
37. Hori, T., Kondo, T., Kanamori, M., Tabuchi, Y., Ogawa, R., Zhao, Q. L., Ahmed, K., Yasuda, T., Seki, S., Suzuki, K., and Kimura, T. (2010) Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. Cancer Lett. 287, 98-108
38. Jehangir, S., and Dowdy, S. F. (2005) Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Del. Rev. 57, 579-596
39. Frankel, A. D., and Pabo, C. O. (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189-1193 (Pubitemid 19020071)
40. Vivès, E., Brodin, P., and Lebleu, B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272, 16010-16017 (Pubitemid 27265584)
41. Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., Kim, M., Desai, N., Young, P., Norton, C. R., Gridley, T., Cardiff, R. D., Cunha, G. R., Abate-Shen, C., and Shen, M. M. (1999) Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13, 966-977 (Pubitemid 29200980)
42. Lei, Q., Jiao, J., Xin, L., Chang, C. J., Wang, S., Gao, J., Gleave, M. E., Witte, O. N., Liu, X., and Wu, H. (2006) NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9, 367-378 (Pubitemid 43668733)
43. Orlicky, S., Tang, X., Willems, A., Tyers, M., and Sicheri, F. (2003) Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell 112, 243-256 (Pubitemid 36144113)
44. Sen, N., Sen, A., and Mackow, E. R. (2007) Degrons at theCterminus of the pathogenic but not the nonpathogenic hantavirus G1 tail direct proteasomal degradation. J. Virol. 81, 4323-4330 (Pubitemid 46586926)
45. Kalejta, R. F., and Shenk, T. (2003) Proteasome-dependent, ubiquitinin-dependent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc. Natl. Acad. Sci. U.S.A. 100, 3263-3268 (Pubitemid 36356571)
46. Kay, B. K., Williamson, M. P., and Sudol, M. (2000) The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J. 14, 231-241 (Pubitemid 30086060)
47. Kaelin, W. G. (2005) Proline hydroxylation and gene expression. Annu. Rev. Biochem. 74, 115-128
48. Yan, Y. T., Stein, S. M., Ding, J., Shen, M. M., and Abate-Shen, C. (2000) A novel PF/PN motif inhibits nuclear localization and DNA binding activity of the ESX1 homeoprotein. Mol. Cell. Biol. 20, 661-671 (Pubitemid 30023108)
49. Kanelis, V., Donaldson, L., Muhandiram, D. R., Rotin, D., Forman-Kay, J. D., and Kay, L. E. (2000) Sequential assignment of proline-rich regions in proteins: application to modular binding domain complexes. J. Biomol. NMR 16, 253-259 (Pubitemid 30217114)
50. Lewis, M. D., and Roberts, B. J. (2004) Role of the C-terminal α-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity. Oncogene 23, 2315-2323 (Pubitemid 38496786)
51. Bess, K. L., Swingler, T. E., Rivett, A. J., Gaston, K., and Jayaraman, P. S. (2003) The transcriptional repressor protein PRH interacts with the proteasome. Biochem. J. 374, 667-675 (Pubitemid 37163912)
52. Melo, S. P., Barbour, K. W., and Berger, F. G. (2011) Cooperation between an intrinsically disordered region and a helical segment is required for ubiquitin-independent degradation by the proteasome. J. Biol. Chem. 286, 36559-36567
53. Papandreou, C. N., and Logothetis, C. J. (2004) Bortezomib as a potential treatment for prostate cancer. Cancer Res. 64, 5036-5043 (Pubitemid 39006513)
54. Tahmatzopoulos, A., Gudegast, C., Stöckle, M., Wullich, B., Unteregger, G., Zwergel, U., and Zwergel, T. (2004) Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer. Aktuelle Urol. 35, 491-496 (Pubitemid 39524595)
55. Moehler, T., and Goldschmidt, H. (2011) Therapy of relapsed and refractory multiple myeloma. Recent Results Cancer Res. 183, 239-271
56. Corallini, F., and Celeghini, C. (2008) The potential role of Nutlins in the treatment of B-chronic lymphocytic leukemia (B-CLL). J. Leukoc. Biol. 84, 651
57. Vassilev, L. T. (2004) Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3, 419-421
58. Adams, J., and Kauffman, M. (2004) Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22, 304-311 (Pubitemid 38725184)
59. Kane, R. C., Bross, P. F., Farrell, A. T., and Pazdur, R. (2003) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8, 508-513 (Pubitemid 37467365)
60. Mack, P. C., Davies, A. M., Lara, P. N., Gumerlock, P. H., and Gandara, D. R. (2003) Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 41, S89-96 (Pubitemid 36819000)
61. Gaczynska, M., Osmulski, P. A., Gao, Y., Post, M. J., and Simons, M. (2003) Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry 42, 8663-8670 (Pubitemid 36899808)